oncnursingnews3h
Accelerated Approval Sought for RP1-Nivolumab Combo for Pretreated Melanoma
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated ...
oncnursingnews2d
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC
The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone ...
oncnursingnews2d
Sabrina Mikan, PhD, RN, ACNS-BC
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews2d
Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews4d
FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers
The FDA granted a fast track designation to ALE-P02 for patients with CLDN1-positive squamous solid tumors. The FDA granted ...
oncnursingnews4d
Rapid Taper Plays Role in Suspected Opioid Misuse in Patients With Cancer
Clinicians should consider a rapid taper approach for patients with cancer who exhibit repeated signs of opioid misuse, an ...
oncnursingnews4d
Eric Blackstone, MA, Sara L. Douglas, PhD, RN, Amy R. Lipson, PhD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5d
Patricia Kropf, MD
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
oncnursingnews5d
Subcutaneous Pembrolizumab Is Noninferior to IV Formulation in NSCLC
Subcutaneous pembrolizumab plus chemotherapy was noninferior to IV pembrolizumab plus chemotherapy in treatment-naïve non-small cell lung cancer. Pembrolizumab (Keytruda) and berahyaluronidase alfa ...